Alagille Syndrome

FDA approves first drug for patients with progressive familial intrahepatic cholestasis

The U.S. Food and Drug Administration has approved odevixibat (Bylvay; Albireo Pharma, Inc) for the treatment of pruritus in all subtypes of progressive familial intrahepatic cholestasis (PFIC), according to a press release. Odevixibat is a non-systemic ileal bile acid transport inhibitor (IBATi). Approval was based on data from two phase...